The White House is reviewing a new prescription drug user fee package agreement reached between the FDA and the biopharma industry for the years 2028 through 2032. The arrangement, under White House examination according to sources, is expected to set the fees the sector will pay to support FDA operations. For biotech stakeholders, user fee reauthorization can affect review staffing, timelines, and the predictability of regulatory throughput. The review also adds an additional governance step between agency-level negotiating and formal implementation. This is particularly relevant for developers with late-stage programs, where review planning and fee-driven resourcing can influence review timelines and operational expectations. Biotech teams will likely monitor whether the package includes changes to performance goals or structural elements of the user fee framework that could affect submission strategies.